Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04347369
Other study ID # XQonc-015
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 17, 2020
Est. completion date December 31, 2020

Study information

Verified date February 2024
Source Xinqiao Hospital of Chongqing
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The research aim to collect large samples of COVID-19 disease patients with clinical symptoms, laboratory and imaging examination data. Screening the biological indicators which are related to the occurrence of severe diseases. Then, investigators using artificial intelligence (AI) technology deep learning method to find a prediction model that can dynamically quantify COVID-19 disease severity.


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date December 31, 2020
Est. primary completion date August 30, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients of COVID-19 disease confirmed by virus nucleic acid RT-PCR and CT Exclusion Criteria: - unconfirmed suspected cases - Patients during pregnancy and lactation - incomplete clinical data - inestigators considered patients ineligible for the trial

Study Design


Related Conditions & MeSH terms


Intervention

Other:
other
clinical diagnosis

Locations

Country Name City State
China Xinqiao Hospital of Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Xinqiao Hospital of Chongqing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary discrimination The performance of our prediction model is evaluated with the receiver operating characteristic (ROC) curves, areas under the curves (AUCs) and concordance index (c-index). up to 3 months
Primary Calibration The calibration curves analysis is used to show error between the predicted clinical phenotype with prediction model and actual clinical phenotype. up to 3 months
Primary Net benefit Decision curve analysis was used to determine whether the models could be considered useful tools for clinical decisionmaking by comparing the net benefits at any threshold. up to 3 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04984408 - Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Phase 3
Terminated NCT04642638 - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure Phase 2/Phase 3
Recruiting NCT04587323 - VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
Completed NCT04682873 - A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus Phase 3
Completed NCT04359212 - Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
Completed NCT05603130 - Epidemiologic Register on Diabetes and COVID-19 in Tunisia
Completed NCT04830800 - A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC Phase 1/Phase 2
Completed NCT04757792 - Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
Active, not recruiting NCT04417257 - Study of LAU-7b for the Treatment of COVID-19 Disease in Adults Phase 2/Phase 3
Recruiting NCT04522037 - Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
Completed NCT04446377 - A Study of LAM-002A for the Prevention of Progression of COVID-19 Phase 2
Active, not recruiting NCT04969172 - A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection Phase 2
Completed NCT04366024 - A Novel Nomogram to Predict Severity of COVID-19
Completed NCT04787510 - COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
Completed NCT05329220 - ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 Phase 3
Active, not recruiting NCT05077267 - ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects Phase 2
Completed NCT04472013 - Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19
Active, not recruiting NCT04371354 - Outcomes of Covid-19 Protective Measures in Endoscopy
Not yet recruiting NCT04779359 - Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease